Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | GOT1 | P17174 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.48 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816494 | 1.00 | KDM4E (0.48) | KDM4ELMNAALDH1A1TP53CYP3A4 | |
| SCHEMBL28657632 | 0.98 | KDM4E (0.47) | KDM4ELMNAALDH1A1TP53CYP3A4 | |
| SCHEMBL28957874 | 0.87 | KDM4E (0.42) | KDM4ELMNAALDH1A1TP53CYP3A4 | |
| SCHEMBL30523852 | 0.87 | KDM4E (0.55) | KDM4ELMNAALDH1A1TP53CYP3A4 | |
| SCHEMBL1673296 | 0.87 | KDM4E (0.55) | KDM4ELMNAALDH1A1TP53CYP3A4 | |
| SCHEMBL27973696 | 0.85 | ALDH1A1 (0.50) | KDM4ELMNAALDH1A1TP53CYP3A4 | |
| SCHEMBL28167414 | 0.85 | NPC1 (0.43) | KDM4ELMNAALDH1A1TP53CYP3A4 | |
| SCHEMBL716145 | 0.85 | KDM4E (0.43) | KDM4ELMNAALDH1A1TP53CYP3A4 | |
| SCHEMBL28877285 | 0.85 | EGFR (0.55) | KDM4ELMNAALDH1A1TP53CYP3A4 | |
| SCHEMBL29361407 | 0.85 | PDK1 (0.51) | KDM4ELMNAALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103594636-B | Based on double TFT organic electroluminescence devices modulated and preparation method thereof | 上海大学 | 2017-07-25 | — | — | CN | claimed |
| EP-0449203-B1 | 4-Phenylphthalazine derivatives | MITSUBISHI CHEM IND (JP) | 1994-12-07 | — | — | EP | claimed |
| US-5089494-A | 4-PHENYLPHTHALAZINE DERIVATIVES WHICH INHIBIT PLATELET AGGREGATION | MITSUBISHI KASEI CORPORATION (JP) | 1992-02-18 | — | — | US | claimed |
| EP-0449203-A1 | 4-Phenylphthalazine derivatives | Mitsubishi Chemical Corporation (JP) | 1991-10-02 | — | — | EP | claimed |
| JP-57048972-A | — | — | None | — | — | JP | disclosed |
| JP-54032489-A | — | — | None | — | — | JP | disclosed |
| JP-56053659-A | — | — | None | — | — | JP | disclosed |
| US-12558354-B2 | Tumor necrosis factor alpha (TNF-alpha) small molecule inhibitor | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-02-24 | — | — | US | disclosed |
| US-12419888-B2 | Methods of treating elevated plasma cholesterol | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2025-09-23 | — | — | US | disclosed |
| CN-115010765-B | Red-light organic electrophosphorescent material and preparation method and application thereof | 安徽工业大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-115160378-B | Red-light organic electrophosphorescent material and preparation method and application thereof | 安徽工业大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-117362661-A | Hyperbranched carbon-nitrogen heterocyclic resin and resin composition, prepreg, circuit substrate and printed circuit board thereof | 浙江华正新材料股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-0159652-B1 | 4-PHENYLPHTHALAZINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MITSUBISHI KASEI CORPORATION (JP) | 1990-07-11 | — | — | EP | disclosed |
| US-4668677-A | ANTIISCHEMIC, ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1987-05-26 | — | — | US | disclosed |
| US-4668677-A | ANTIISCHEMIC, ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1987-05-26 | — | — | US | disclosed |
| EP-0159652-A2 | 4-Phenylphthalazine derivatives, their preparation and pharmaceutical compositions containing them | MITSUBISHI KASEI CORPORATION (JP) | 1985-10-30 | — | — | EP | disclosed |
| EP-0159652-A2 | 4-Phenylphthalazine derivatives, their preparation and pharmaceutical compositions containing them | MITSUBISHI KASEI CORPORATION (JP) | 1985-10-30 | — | — | EP | disclosed |
| JP-S5748972-A | 4-PHENYLPHTHALAZINE DERIVATIVE | MITSUBISHI YUKA YAKUHIN KK | 1982-03-20 | — | — | JP | disclosed |
| JP-S5653659-A | BLOOD PLATELET COAGULATION SUPPRESSING AGENT | MITSUBISHI YUKA YAKUHIN KK | 1981-05-13 | — | — | JP | disclosed |
| JP-S5432489-A | 4-SUBSTD PHENYLPHTHARAZINE DERIVATIVES | DAI ICHI SEIYAKU CO LTD | 1979-03-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558354-B2 | Tumor necrosis factor alpha (TNF-alpha) small molecule inhibitor | TNF, TNFRSF1A, TNFRSF9 | KDM4E 4752/4885LMNA 3419/4885ALDH1A1 2971/4885 |
| US-12419888-B2 | Methods of treating elevated plasma cholesterol | PCSK9, LDLR, CETP | KDM4E 3110/4885LMNA 615/4885ALDH1A1 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.